Merck's acquisition of Sigma-Aldrich close to completion
Twelve months after pharmaceutical company Merck announced its intention to buy US life science company Sigma-Aldrich, steady progress has been made towards closing the deal.
On 22 September 2014, Merck revealed its agreement with Sigma-Aldrich to purchase the latter for US$17 billion — US$140 cash per share — establishing itself as one of the leading players in the US$130 billion global life science industry. The merged company will be led by Merck Millipore CEO Udit Batra.
On 11 August 2015, Sigma-Aldrich and Merck announced they had obtained all necessary antitrust approvals, with the approval of the European Commission (EC) being conditional upon the sale of parts of Sigma-Aldrich’s solvents and inorganics business in Europe. Negotiations with potential buyers are now in the final stage.
Once a binding agreement has been signed, the EC must approve the buyer before Merck can complete the Sigma-Aldrich acquisition. Completion is expected within the next two months.
Director of scientific R&D firm fined $195K+ over biogas experiments
The fine follows a 2022 incident in which a doctor sustained serious injuries after exposure to...
7th edition of STEM Equity Monitor now available
The latest national data resource on diversity in STEM has new design features intended to...
Professor Girish Dwivedi wins 2026 WA Pearcey Entrepreneur of the Year Award
As part of the 35th annual WAITTA INCITE Awards, Dwivedi was recognised for his contribution to...
